Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 201 to 250 of 2462

TitleReference numberPublishedLast updated
TuberculosisNG33
Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and overTA949
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and overTA950
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancerTA951
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatmentsTA947
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatmentsTA948
Caesarean birthNG192
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal)TA945
Devices for remote monitoring of Parkinson's diseaseDG51
COVID-19 rapid guideline: managing the long-term effects of COVID-19NG188
Skin cancerQS130
Pharyngeal electrical stimulation for neurogenic dysphagiaIPG781
Temperature control to improve neurological outcomes after cardiac arrestIPG782
Neonatal infectionQS75
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancerTA946
Sebelipase alfa for treating Wolman diseaseHST30
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancerTA944
Intravascular lithotripsy for calcified arteries in peripheral arterial diseaseIPG780
Bipolar disorder: assessment and managementCG185
Epilepsies in children, young people and adultsQS211
Targeted-release budesonide for treating primary IgA nephropathyTA937
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)TA940
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)TA941
Empagliflozin for treating chronic kidney diseaseTA942
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetesTA943
Risdiplam for treating spinal muscular atrophyTA755
Digitally enabled therapies for adults with anxiety disorders: early value assessmentHTE9
Middle meningeal artery embolisation for chronic subdural haematomasIPG779
Cardiovascular disease: risk assessment and reduction, including lipid modificationNG238
Transition from children's to adults' servicesQS140
Velmanase alfa for treating alpha-mannosidosisHST29
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939
Acne vulgaris: managementNG198
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)TA938
Secukinumab for treating moderate to severe hidradenitis suppurativaTA935
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)TA936
Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolismIPG778
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)TA933
Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptomsTA934
Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)TA932
Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosisIPG777
Zanubrutinib for treating chronic lymphocytic leukaemiaTA931
Transient loss of consciousness ('blackouts') in over 16sCG109
Hypertension in adults: diagnosis and managementNG136
Suspected acute respiratory infection in over 16s: assessment at first presentation and initial managementNG237
Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessmentHTE15
Biodegradable subacromial spacer insertion for rotator cuff tearsIPG775
Extracorporeal carbon dioxide removal for acute respiratory failureIPG776
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatmentsTA930
Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancerCG164

Results per page

  1. 10
  2. 25
  3. 50
  4. All